Table II. We hereby certify to you as follows:
Table II. Item Loadings for a PCA with FS and FA Items with Data from Wave 1 Component 1 Component 2 FSSoM1 .84 FSSoM2 .62 FSSoM3 .83 FSFRW1 .90 FSFRW2 .82 FSFRW3 .87 FSSTF1 .59 FSSTF2 .76 FSSTF3 .34 FSLoC1 .57 FSLoC2 FSLoC3 .80 .43 FADFD1 .83 FADFD2 .87 FADFD3 .84 FADFD4 .67 FAAFI1 .57 FAAFI2 .58 .32 FAAFI3 .58 FAAFI4 .54
Table II. Supervisor Allowance Xxx Xxxxx Effective until June 9, 2022 $6,611 Effective June 10, 2022, 0.50% Increase $6,644 Effective September 1, 2022, 1.25% Increase $6,727 Effective September 1, 2023, 2.00% Increase $6,862
Table II. Objective and subjective voice frequency and virilizing adverse events per dosage group. GH+Pl GH+Ox GH+Ox GH+Ox 0.06 GH+Ox (N = 30) 0.03 0.03 vs. (N = 27) 0.06 vs. Outcome (N = 31) GH+Pl GH+Pl P Value P Value Voice frequency at starting Ox/Pl (all age groups) – SDS†‡ Age group 1 (after previous GH therapy) – SDS† 1.1±1.2** 0.6±1.2 0.9±1.4** 0.4±1.6 1.0±0.9** 1.0±1.0 Age groups 2 and 3 (at baseline) – SDS† 1.2±1.2** 1.1±1.4** 1.0±0.9** Change in voice frequency during Ox/Pl (all age groups) – SDS/yr, SE§ -0.05, 0.05 -0.17, 0.05 0.09 -0.27, 0.06 0.007 Age group 1 (after previous GH therapy) – SDS/yr, SE -0.02, 0.08 -0.13, 0.09 0.3 -0.29, 0.10 0.04 Age groups 2 and 3 – SDS/yr, SE -0.06, 0.07 -0.21, 0.06 0.1 -0.22, 0.09 0.2 Change in voice frequency during Ox/Pl without outliers – SDS/yr, SE¶ -0.07, 0.05 -0.16, 0.05 0.2 -0.26, 0.06 0.02 Voice frequency at the last measurement – SDS 0.6±0.7** 0.3±1.2 0.4 -0.2±1.6 0.06 Girls reporting subjective voice deepening – n (%) 10 (33%) 13 (42%) 0.5 14 (52%) 0.2 Girls reporting virilization other than voice deepening during Ox/Pl – n (%)║ 1 (3%) 5 (16%) 0.2 8 (30%) 0.01 Hirsutism 1 (3%) 4 (13%) 0.4 8 (30%) 0.01 Mild clitoromegaly 0 (0%) 4 (13%) 0.1 4 (15%) 0.04 * values are expressed as means±SD, unless otherwise indicated. † No statistical tests were applied to assess differences between the dosage groups at starting Ox/Pl. ‡ Based on 18, 19 and 11 tests in GH+Pl, GH+Ox 0.03 and GH+Ox 0.06, respectively. These recordings were included in repeated measurements analyses, which takes into account missing data. § Based on 123, 149 and 92 tests during Ox/Pl and 20, 26, 21 tests at the last measurement (i.e. at or after discontinuation of Ox/Pl) in GH+Pl, GH+Ox 0.03 and GH+Ox 0.06, respectively. ¶ Five voice recordings (of two girls) that displayed a voice frequency higher than 4.5 SDS were identiefied as outliers. ║ Some patients reported hirsutism as well as clitoromegaly, while others reported only one these complaints. The number of the patients reporting both adverse event may therefore not equal the numbers in this row. ** Significantly different from 0 SDS (i.e. from healthy Dutch girls, P<0.05). GH+Pl GH+Ox 0.03 GH+Ox 0.06 60 50 % of patients 40 10 0 voice voice breaks hoarseness voice has voice has voice has nasal sound deepening become become become softer higher louder
Table II. The population estimates obtained from the simultaneous fitting of the in vivo data, the in vitro transport across DRS and the in vitro transport across RSC upon transdermal iontophoresis of 5-OH-DPAT. Data Para- meter Unit Theta Eta Sigma mean %RSE mean %RSE mean %RSE In vivo Jss KR CL Q V2 V3 K24 K42 Kout IC50 Imax sigma1 sigma2 nmol cm-2 h-1 h-1 L h-1 L h-1 L L h-1 h-1 h-1 xx xx-1 - - - 31.80 4.41 1.00 3.70 0.46 1.49 0.02 31.80 4.61 0.21 0.95 -- 20 31 18 9 15 12 178 180 16 26 3-- 0.22 0.51 0.35 - 0.12 0.07 - - 1.21 3.98 0.03 -- 52 68 40 - 51 51 - - 37 81 30 -- - - - - - - - - - - - 0.02 0.06 ---------- - 19 35 In vitro across DRS Jss KR tL Jpas sigma1 sigma2 nmol cm-2 h-1 h-1 h nmol cm-2 h-1 -- 39.00 1.45 0.24 3.89 -- 566 12 -- 0.02 0.19 0.02 0.28 -- 31 32 76 44 -- - - - - 0.001 0.31 --- - 24 42 In vitro across RSC Jss KR tL Jpas sigma1 nmol cm-2 h-1 h-1 h nmol cm-2 h-1 - 62.70 2.58 0.04 2.49 - 10 1 66 5- 0.03 0.03 0.51 0.01 - 52 46 187 34 - - - - - 0.004 --- - 20 Analogous to the in vivo data, goodness of fit for the in vitro iontophoretic transport was evaluated graphically (Figs. 6B and Fig 6C, respectively for the transport in DRS and in RSC) as well as statistically by calculating bias and precision parameters (Table I). No bias was observed for either population or individual parameter estimates (p>0.05), confirming the accuracy of the model for iontophoretic transport in DRS and in RSC. A summary of the population parameters of the models of the in vitro iontophoretic transport across DRS and RSC is presented in Table II. In the transport across DRS and RSC, all the fixed-effects parameters were estimated with a reliable precision. The residual errors of the in vitro transport across DRS and RSC were relatively small as indicated by the values of sigma1 in both models. 40 A 80 70 60 50 40 30 20 10 0 B 40 80 70 60 50 40 30 20 10 0 C 60
Table II. Characteristics of the interventions of included studies
Table II. The Advance Rates in Table I shall be subject to reduction based on the aggregate number of Portfolio Investments held by the Obligors and the percentage of the Borrowing Base attributable to the Aggregate First Lien Contribution as follows: 70 #4841-8625-7971v16 II(a) Greater than or equal to 15 Less than 50% Portfolio Investment Cash, Cash Equivalents and Short-Term Quoted Unquoted U.S. Government Securities 100% n.a. Long-Term U.S. Government Securities 95% n.a. Performing First Lien Bank Loans 70% 60% Second Out Portions of Performing Unitranche Bank Loans 65% 55% Performing Second Lien Bank Loans 60% 50% Performing Cash Pay High Yield Securities 50% 40% Performing Covenant-Lite Loans 50% 40% Performing Cash Pay Mezzanine Investments 45% 35% II(b) Greater than or equal to 12, but less than 15 Greater than or equal to 55% Portfolio Investment Cash, Cash Equivalents and Short-Term U.S. Government Securities Quoted 100% Unquoted n.a. Long-Term U.S. Government Securities 95% n.a. Performing First Lien Bank Loans 70% 60% Second Out Portions of Performing Unitranche Bank Loans 65% 55% Performing Second Lien Bank Loans 60% 50% Performing Cash Pay High Yield Securities 50% 40% Performing Covenant-Lite Loans 50% 40% Performing Cash Pay Mezzanine Investments 45% 35% II(c) Greater than or equal to 12, but less than 15 Less than 55% Portfolio Investment Cash, Cash Equivalents and Short-Term U.S. Government Securities Quoted 100% Unquoted n.a. Long-Term U.S. Government Securities 95% n.a. Performing First Lien Bank Loans 65% 55% #4841-8625-7971v16 Second Out Portions of Performing Unitranche Bank Loans 60% 50% Performing Second Lien Bank Loans 55% 45% Performing Cash Pay High Yield Securities 45% 35% Performing Covenant-Lite Loans 45% 35% Performing Cash Pay Mezzanine Investments 40% 30% II(d) Greater than or equal to 10, but less than 12 Greater than or equal to 60% Portfolio Investment Cash, Cash Equivalents and Short-Term U.S. Government Securities Quoted 100% Unquoted n.a. Long-Term U.S. Government Securities 95% n.a. Performing First Lien Bank Loans 65% 55% Second Out Portions of Performing Unitranche Bank Loans 60% 50% Performing Second Lien Bank Loans 55% 45% Performing Cash Pay High Yield Securities 45% 35% Performing Covenant-Lite Loans 45% 35% Performing Cash Pay Mezzanine Investments 40% 30% II(e) Greater than or equal to 10, but less than 12 Less than 60% Portfolio Investment Cash, Cash Equivalents and Short-Term U.S. Government Securities Quoted 100% U...
Table II. Applicable Margin Tier Consolidated Leverage Base Eurodollar ---- Ratio Rate Rate --------------------- ------ ---------- V Greater than or equal to 2.50 to 1.00 0.75% 2.00% IV Less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00 0.50% 1.75% III Less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00 0.25% 1.50% II Less than 1.00 to 1.00 but greater than or equal to 0.50 to 1.00 0.00% 1.25% I Less than 0.50 to 1.00 0.00% 1.00% The Applicable Margin shall be established at the end of each fiscal quarter of the Borrower (each, a "Determination Date"). Any change in the Applicable Margin following each Determination Date shall be determined based upon the computations set forth in the certificate furnished to the Agent pursuant to Section 7.1(a)(ii) and Section 7.1(b)(ii), subject to review and approval of such computations by the Agent, and shall be effective commencing on the fifth day following the date such certificate is received until the first day following the date on which a new certificate is delivered or is required to be delivered, whichever shall first occur; provided however, if the Borrower shall fail to deliver any such certificate within the time period required by Section 7.1, then the Applicable Margin shall be Tier V until the appropriate certificate is so delivered. From the Closing Date to the day following the date of delivery of the certificate for the first Determination Date, the Applicable Margin shall be .25% for Base Rate Loans and 1.50% for Eurodollar Rate Loans.
Table II. Summary of Necessary Dynamic- and Fixed- Convergence Parameters
Table II. First year of service $2,083 Second year of service $2,684 Third year of service $3,124 Maximum allowance per annum $3,124
